CO6361924A2 - Nuevas lactamas como inhibidores de beta secretasa - Google Patents

Nuevas lactamas como inhibidores de beta secretasa

Info

Publication number
CO6361924A2
CO6361924A2 CO11063882A CO11063882A CO6361924A2 CO 6361924 A2 CO6361924 A2 CO 6361924A2 CO 11063882 A CO11063882 A CO 11063882A CO 11063882 A CO11063882 A CO 11063882A CO 6361924 A2 CO6361924 A2 CO 6361924A2
Authority
CO
Colombia
Prior art keywords
secretasa
lactamas
inhibitors
beta
new
Prior art date
Application number
CO11063882A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Brian Thomas Oneill
Ivan Voktorovich Efremov
Christopher John Helal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41481076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6361924(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CO6361924A2 publication Critical patent/CO6361924A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se desvelan compuestos y sales farmacéuticamente aceptables de los compuestos, en los que los compuestos tienen la estructura de la Fórmula Icomo se define en la memoria descriptiva. También se desvelan composiciones farmacéuticas, procedimientos de tratamiento, procedimientos de síntesis e intermedios correspondientes.
CO11063882A 2008-11-23 2011-05-24 Nuevas lactamas como inhibidores de beta secretasa CO6361924A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11722508P 2008-11-23 2008-11-23

Publications (1)

Publication Number Publication Date
CO6361924A2 true CO6361924A2 (es) 2012-01-20

Family

ID=41481076

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11063882A CO6361924A2 (es) 2008-11-23 2011-05-24 Nuevas lactamas como inhibidores de beta secretasa

Country Status (28)

Country Link
US (1) US20110224231A1 (es)
EP (1) EP2370439A1 (es)
JP (2) JP4932065B2 (es)
KR (1) KR20110086769A (es)
CN (1) CN102317289A (es)
AP (1) AP2011005725A0 (es)
AU (1) AU2009318855A1 (es)
BR (1) BRPI0922799A2 (es)
CA (1) CA2743584A1 (es)
CL (1) CL2011001147A1 (es)
CO (1) CO6361924A2 (es)
CR (1) CR20110269A (es)
CU (1) CU20110113A7 (es)
DO (1) DOP2011000134A (es)
EA (1) EA201170722A1 (es)
EC (1) ECSP11011073A (es)
GE (1) GEP20135806B (es)
IL (1) IL212869A0 (es)
MA (1) MA32929B1 (es)
MX (1) MX2011005346A (es)
NI (1) NI201100096A (es)
NZ (1) NZ592823A (es)
PE (1) PE20110777A1 (es)
SV (1) SV2011003916A (es)
TN (1) TN2011000252A1 (es)
UA (1) UA99787C2 (es)
WO (1) WO2010058333A1 (es)
ZA (1) ZA201103738B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
KR20120001756A (ko) 2009-03-13 2012-01-04 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
BR112013018973A2 (pt) * 2011-01-25 2017-09-19 Bayer Ip Gmbh processo para a preparação de derivados de 1-h-pirrolidina-2,4-diona
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
WO2014052398A1 (en) 2012-09-28 2014-04-03 Vitae Pharmaceuticals, Inc. Inhibitor of beta-secretase
CN106488912A (zh) * 2014-07-14 2017-03-08 默沙东公司 肾外髓质钾通道的抑制剂
WO2016008064A1 (en) * 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
FR2824901B1 (fr) * 2001-05-21 2003-09-12 Poudres & Explosifs Ste Nale Procede et installation de destruction de fusee montee sur une munition
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物
CA2554920C (en) * 2004-02-17 2011-12-06 Herm. Sprenger Gmbh & Co. Kg Double-jointed bit for horses
AU2005294448B2 (en) * 2004-10-07 2011-07-14 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2006044497A2 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
CA2608718A1 (en) * 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
US8211904B2 (en) * 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
AU2005336531B2 (en) * 2005-09-20 2012-01-12 Sca Hygiene Products A.B. Dispenser
EP2021003B1 (en) * 2006-05-26 2010-07-21 Eisai R&D Management Co., Ltd. Imidazoazephinone compounds
KR20090029703A (ko) * 2006-05-26 2009-03-23 에자이 알앤드디 매니지먼트 가부시키가이샤 이미다조아제피논 화합물
US8124613B2 (en) * 2006-06-14 2012-02-28 Virochem Pharma Inc. Spirotropane compounds
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
JP2010505833A (ja) * 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのマクロ環式スピロピペリジンβ−セクレターゼ阻害剤
WO2008054698A2 (en) * 2006-10-30 2008-05-08 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
EA201170722A1 (ru) 2011-10-31
AU2009318855A1 (en) 2010-05-27
NI201100096A (es) 2011-10-31
AP2011005725A0 (en) 2011-06-30
ZA201103738B (en) 2012-01-25
JP2012509310A (ja) 2012-04-19
US20110224231A1 (en) 2011-09-15
SV2011003916A (es) 2011-07-28
CL2011001147A1 (es) 2011-09-30
TN2011000252A1 (fr) 2012-12-17
UA99787C2 (en) 2012-09-25
CU20110113A7 (es) 2012-01-31
MA32929B1 (fr) 2012-01-02
GEP20135806B (en) 2013-04-10
ECSP11011073A (es) 2011-06-30
JP2012107029A (ja) 2012-06-07
CN102317289A (zh) 2012-01-11
JP4932065B2 (ja) 2012-05-16
KR20110086769A (ko) 2011-07-29
DOP2011000134A (es) 2011-07-31
CA2743584A1 (en) 2010-05-27
BRPI0922799A2 (pt) 2019-09-24
NZ592823A (en) 2012-12-21
EP2370439A1 (en) 2011-10-05
CR20110269A (es) 2011-07-04
WO2010058333A1 (en) 2010-05-27
MX2011005346A (es) 2011-06-16
IL212869A0 (en) 2011-07-31
PE20110777A1 (es) 2011-10-29

Similar Documents

Publication Publication Date Title
UY31189A1 (es) Compuestos heterocíclicos
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
UY30500A1 (es) Compuestos de azabencimidazolilo
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CU20110145A7 (es) Derivados de sulfonamida
CO6470898A2 (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
UY33075A (es) Derivados de ciclohexano y usos de los mismos
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
CR20110680A (es) Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas
CO6741154A2 (es) Compuestos de triazolopiridina
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
EA201290229A1 (ru) Производные спиролактама и их применение
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
CU20100210A7 (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
HN2011002992A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed